Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 8/20 | 0.54 |
| ▸ | MAPT | P10636 | 8/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 5/20 | 0.45 |
| ▸ | USP2 | O75604 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1736731 | 1.00 | LMNA (0.54) | LMNAMAPTSMN1; SMN2HTTKMT2A | |
| SCHEMBL1734779 | 0.97 | MAPT (0.52) | LMNAMAPTSMN1; SMN2HTTKMT2A | |
| SCHEMBL1734775 | 0.97 | MAPT (0.52) | LMNAMAPTSMN1; SMN2HTTKMT2A | |
| SCHEMBL1735837 | 0.97 | MAPT (0.52) | LMNAMAPTSMN1; SMN2HTTKMT2A | |
| SCHEMBL1736992 | 0.93 | LMNA (0.49) | LMNAMAPTSMN1; SMN2HTTKMT2A | |
| SCHEMBL1734863 | 0.91 | LMNA (0.49) | LMNAMAPTSMN1; SMN2HTTKMT2A | |
| SCHEMBL1734694 | 0.91 | LMNA (0.59) | LMNAMAPTSMN1; SMN2HTTKMT2A | |
| SCHEMBL1734860 | 0.91 | LMNA (0.49) | LMNAMAPTSMN1; SMN2HTTKMT2A | |
| SCHEMBL1734690 | 0.91 | LMNA (0.59) | LMNAMAPTSMN1; SMN2HTTKMT2A | |
| SCHEMBL1735653 | 0.91 | MAPT (0.48) | LMNAMAPTSMN1; SMN2HTTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2142533-B1 | IMIDAZOLIDINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-11-16 | — | — | EP | claimed |
| WO-2011069003-A3 | METHODS AND SYSTEMS FOR THE TREATMENT OF ANXIETY DISORDERS AND DISORDERS WITH PSYCHOTIC FEATURES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-10-27 | — | — | WO | claimed |
| EP-2142533-A1 | IMIDAZOLIDINONE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-01-13 | — | — | EP | claimed |
| US-7625902-B2 | Imidazolidinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-12-01 | — | — | US | claimed |
| WO-2008119657-A1 | IMIDAZOLIDINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-09 | — | — | WO | claimed |
| US-20080242677-A1 | IMIDAZOLIDINONE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-10-02 | — | — | US | claimed |
| EP-2142533-B1 | IMIDAZOLIDINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-11-16 | — | — | EP | disclosed |
| WO-2011069003-A3 | METHODS AND SYSTEMS FOR THE TREATMENT OF ANXIETY DISORDERS AND DISORDERS WITH PSYCHOTIC FEATURES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-10-27 | — | — | WO | disclosed |
| EP-2142533-A1 | IMIDAZOLIDINONE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2010-01-13 | — | — | EP | disclosed |
| US-7625902-B2 | Imidazolidinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-12-01 | — | — | US | disclosed |
| WO-2008119657-A1 | IMIDAZOLIDINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-09 | — | — | WO | disclosed |
| US-20080242677-A1 | IMIDAZOLIDINONE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242677-A1 | IMIDAZOLIDINONE DERIVATIVES | NR1H2, NR1H3, NR1I2 | LMNA 1252/4885MAPT 4023/4885SMN1; SMN2 3502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.